Monday, 26 Jun 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
06 May 2016 Social 3852 pregnancies found 1.6% w/ UCTD & 0.7% w/ CTD(RA, SLE, Sjog). Thyroid Abs assoc w/ 3x risk of preg complications
06 May 2016 Social A FREE Patient Guide to Biologic Use - available now at the RheumNow Website. 13 pages jammed with Patient Education
05 May 2016 Slide of the day Patient Guide to Biologics
05 May 2016 Social There is insufficient evidence that platelet rich plasma treatment benefits patellar tendinopathy.
04 May 2016 Blog Biologic Prescribing and Patient Education
03 May 2016 Social Simple patient article on new Remicade Biosimilar for RA, Psoriatic, Crohns, etc. But it wont be available till 2017
25 Apr 2016 News Can Rituximab Change the Course of Interstitial Lung Disease?
20 Apr 2016 Blog Do's and Don'ts of Vaccination: a (Very) Brief Guide for Rheumatologists
15 Apr 2016 Social Tocilizumab to remain a second line treatment for polymyalgia rheumatica. More RCT needed @DrPetryna
14 Apr 2016 News Biosimilar Reports - April 2016
11 Apr 2016 News A Rocky Start for Biosimilar Inflectra?
06 Apr 2016 Social The newly approved biosimilar of Remicade is called Inflectra - generic name infliximab-dyyb - shouldnt that have been infliximab DIY?
05 Apr 2016 Social RT @WIRheum: FDA approves Inflectra, a biosimilar to Remicade
04 Apr 2016 Social #Sjogrens metanalysis of 5 RCTs, 276pt, shows Rituximab had no effect on Schirmers, fatigue, ESSDAI & SF36 @ wk24.
03 Apr 2016 Social IMS Health estimates $92 billion in global sales of branded drugs & biological products will have lost patent protection between 2011 & 2015
01 Apr 2016 Social RT @ACRheum: ACR supports @US_FDA draft guidance on biosimilars labeling; encourages added measures to ensure safety & efficacy: https://t.…
25 Mar 2016 Social EMA will re-review Pfizers application to license Xeljanz 5 mg bid for RA in the EU.
20 Mar 2016 Social Tofacitinib meets primary endpoints in ulcerative colitis trials, achieving 16-18% remission rates
16 Mar 2016 News IL-6 Inhibition Makes News
15 Mar 2016 Social 63 Actemra nonresponders switched to TNFi (41) or Orencia (22) - more TNFi achieved LDAS (CDAI<10) (64% vs 24% ABA)